Lung - Best of ASTRO 2019

Highlights from the best scientific abstracts in thoracic radiotherapy from ASTRO 2019 will be reviewed and placed in perspective with current literature, practice guidelines and patterns of care.  Attendees should leave with a better understanding of how to incorporate these data into daily practice. The 2019 planning committees reviewed potential barriers in patient management and noted that in the treatment of thoracic malignancies, advances are reported almost daily and failure to stay informed can lead to missed opportunities to improve patient care and outcomes. It is increasingly challenging for the clinician to optimally incorporate these advances into daily practice while understanding observed toxicities and adverse interactions, particularly as related to hypofractionation, postoperative radiation and immunotherapy. The management of small cell lung cancer continues to evolve, particularly with respect to PCI and thoracic radiotherapy and new outcome and toxicity data will be reviewed.

This activity is available from November 16, 2019, through 11:59 p.m. Eastern time on November 15, 2022.
 
This activity was originally recorded at ASTRO’s 2019 Best of ASTRO, November 14-16, 2019  in Washington, DC.

Target Audience

The activity is designed to meet the interests of radiation oncologists, medical oncologists and radiation oncology residents.

Learning Objectives

  • Identify evidence for the prophylactic role of radiation in small cell lung cancer.
  • Recognize the role of advanced radiation techniques such as hippocampal-sparing prophylactic cranial irradiation and stereotactic ablative radiotherapy in small cell lung cancer.
  • Analyze the evidence for hypofractionation in thoracic radiotherapy for non-small cell lung cancer, as well as potential risks or toxicities of its use outside of clinical trials.
  • Describe new evidence regarding cardiac dose recommendations for thoracic radiotherapy.
  • Evaluate recent evidence or ongoing studies evaluating the incorporation of immunotherapy with thoracic radiotherapy (standard/hypofractionated/SBRT) in the definitive, metastatic or oligometastatic setting.
Course summary
Available credit: 
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
  • 1.00 SA-CME

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

    The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.

Course opens: 
11/16/2019
Course expires: 
11/15/2022
Cost:
$105.00
Rating: 
0

Inga Grills, MD is employed at Beaumont Health System and has no other disclosures.

The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.

 

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
  • 1.00 SA-CME

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.

    The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.

Price

Cost:
$105.00
Please login or register to take this course.

Course Fees:

ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.

  • Nonmember: $105
  • Member: $55

Policies:

No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.